About Entrez
Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut My
NCBI
Related
Resources Order Documents NLM
Mobile NLM Catalog NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central |
|
Note: |
|
Performing your original search, ovestin vaginal
cream, in PubMed will retrieve 20
citations. |
Display Show |
|
|
|
-
Ovestin vaginal cream and suppositories for the
treatment of menopausal vaginal atrophy.
Trevoux
R, van
der Velden WH, Popovic
D.
Eighty-two postmenopausal women with vaginal atrophy
and associated symptoms were treated with either Ovestin vaginal cream
(54 women) or vaginal suppositories (28 women) containing 0.5 mg of
E3/dose, daily for 3 weeks. A maintenance dose of 0.5 mg of E3 twice
weekly was applied by all patients for 5 weeks, and by 27 of them for up
to 16 weeks. Variables studied were clinical and colposcopic findings,
the Maturation Index (MI) and Maturation Value (MV), cervical mucus
ferning (F) and spinnbarkeit (S) and endometrial biopsies (obtained
pretreatment and after 3 weeks in 15 of the patients). Furthermore, the
bio-availability of circulating unconjugated E3 for up to 8 hours
following a single dose of Ovestin cream was studied in 10 of the
patients. Clinical and colposcopic findings indicated that the treatment
had a very favourable effect in all patients. This was reflected in the
pronounced change in vaginal smears, indicating a strong oestrogenic
effect. There was a slight to moderate effect on cervical mucus.
Endometrial biopsies showed that endometrium remained atrophic in all 15
patients in whom biopsies were obtained. A maintenance dose of 0.5 mg of
E3 twice weekly appeared to be sufficient to maintain the beneficial
effect. Tolerance was good, and patients commented favourably on the
treatment.
PMID: 7141096 [PubMed - indexed for MEDLINE]
Display Show |
| |